Management of hepatitis B: summary of a clinical research workshop (Q36773747)

16 August 2017

1 reference

title

Management of hepatitis B: summary of a clinical research workshop (English)

1 reference

16 August 2017

0 references

1 reference

Jay H Hoofnagle

1

1 reference

16 August 2017

Edward Doo

2

1 reference

16 August 2017

T Jake Liang

3

1 reference

16 August 2017

Russell Fleischer

4

1 reference

16 August 2017

Anna S F Lok

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

45

1 reference

16 August 2017

4

1 reference

16 August 2017

1056-1075

1 reference

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

16 August 2017

1 reference

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

Sampling variability of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

21 January 2018

1 reference

Reappearance of Hepatitis B Virus in Immune Patients Infected with the Human Immunodeficiency Virus Type 1

21 January 2018

1 reference

Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies

21 January 2018

1 reference

X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo

21 January 2018

1 reference

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

Native hepatitis B virions and capsids visualized by electron cryomicroscopy

21 January 2018

1 reference

7 January 2021

Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection

1 reference

7 January 2021

Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.

1 reference

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

7 January 2021

Hepatocyte turnover during resolution of a transient hepadnaviral infection

1 reference

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

7 January 2021

Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice

1 reference

7 January 2021

Noncytolytic control of viral infections by the innate and adaptive immune response

1 reference

7 January 2021

Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice.

1 reference

7 January 2021

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

7 January 2021

Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers

1 reference

7 January 2021

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

1 reference

7 January 2021

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

1 reference

7 January 2021

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection

1 reference

7 January 2021

Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion

1 reference

7 January 2021

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

1 reference

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

7 January 2021

Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene

1 reference

7 January 2021

Hepatitis B virus genotypes in the United States: results of a nationwide study

1 reference

7 January 2021

Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B

1 reference

7 January 2021

From hepatitis to hepatoma: lessons from type B viral hepatitis

1 reference

7 January 2021

1 reference

7 January 2021

Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma

1 reference

7 January 2021

Chronic type B hepatitis and the "healthy" HBsAg carrier state

1 reference

7 January 2021

The natural history of asymptomatic hepatitis B surface antigen carriers

1 reference

7 January 2021

Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.

1 reference

7 January 2021

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

7 January 2021

Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion

1 reference

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

7 January 2021

Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

1 reference

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

7 January 2021

Natural history of hepatitis B.

1 reference

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

7 January 2021

Use of virologic assays in the diagnosis and management of hepatitis C virus infection

1 reference

7 January 2021

Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels.

1 reference

7 January 2021

Dynamic range and reproducibility of hepatitis B virus (HBV) DNA detection and quantification by Cobas Taqman HBV, a real-time semiautomated assay

1 reference

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

7 January 2021

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

7 January 2021

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

7 January 2021

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

7 January 2021

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

7 January 2021

Molecular virology and the development of resistant mutants: implications for therapy

1 reference

7 January 2021

Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences

1 reference

7 January 2021

Hepatitis B virus-related cirrhosis: natural history and treatment

1 reference

7 January 2021

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

1 reference

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

7 January 2021

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

1 reference

7 January 2021

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

1 reference

7 January 2021

Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis

1 reference

7 January 2021

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype

1 reference

7 January 2021

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

1 reference

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

7 January 2021

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.

1 reference

7 January 2021

Variant of hepatitis B virus with primary resistance to adefovir

1 reference

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

7 January 2021

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

1 reference

7 January 2021

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

1 reference

7 January 2021

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

7 January 2021

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

7 January 2021

Tenofovir disoproxil fumarate

1 reference

7 January 2021

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

1 reference

7 January 2021

Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus

1 reference

7 January 2021

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

1 reference

7 January 2021

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

7 January 2021

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

1 reference

7 January 2021

TIPS versus paracentesis for the treatment of refractory ascites

1 reference

7 January 2021

Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

1 reference

7 January 2021

Clinical trial of lamivudine in children with chronic hepatitis B.

1 reference

7 January 2021

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study

1 reference

7 January 2021

Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study

1 reference

7 January 2021

Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial

1 reference

7 January 2021

Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B

1 reference

7 January 2021

The use of lamivudine for patients with acute hepatitis B (a series of cases).

1 reference

7 January 2021

Lamivudine treatment for acute severe hepatitis B: a pilot study

1 reference

7 January 2021

Viral hepatitis and liver transplantation

1 reference

7 January 2021

Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective

1 reference

7 January 2021

1 reference

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

7 January 2021

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

7 January 2021

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

1 reference

7 January 2021

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

1 reference

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

7 January 2021

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

7 January 2021

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

7 January 2021

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

7 January 2021

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

1 reference

7 January 2021

Survival in patients with HIV infection and viral hepatitis B or C: a cohort study

1 reference

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

7 January 2021

Mortality for Liver Disease in Patients With HIV Infection: A Cohort Study

1 reference

7 January 2021

1 reference

7 January 2021

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy

1 reference

7 January 2021

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

1 reference

7 January 2021

Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment

1 reference

7 January 2021

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

1 reference

7 January 2021

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

1 reference

7 January 2021

Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002.

1 reference

7 January 2021

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

1 reference

7 January 2021

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study

1 reference

7 January 2021

Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

1 reference

7 January 2021

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

1 reference

7 January 2021

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

1 reference

7 January 2021

Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy

1 reference

7 January 2021

Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

1 reference

7 January 2021

Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature

1 reference

7 January 2021

Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV

1 reference

7 January 2021

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

1 reference

7 January 2021

Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy

1 reference

7 January 2021

Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc

1 reference

7 January 2021

Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation

1 reference

7 January 2021

Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation.

1 reference

7 January 2021

Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.

1 reference

7 January 2021

Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

1 reference

7 January 2021

Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion

1 reference

7 January 2021

Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.

1 reference

7 January 2021

Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure

1 reference

7 January 2021

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies

1 reference

7 January 2021

The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy

1 reference

7 January 2021

Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy.

1 reference

7 January 2021

Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection

1 reference

7 January 2021

Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids

1 reference

7 January 2021

Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

7 January 2021

Selection of peptide inhibitors of interactions involved in complex protein assemblies: association of the core and surface antigens of hepatitis B virus.

1 reference

7 January 2021

Inhibition of hepatitis B virus in mice by RNA interference

1 reference

7 January 2021

Restoring function in exhausted CD8 T cells during chronic viral infection

1 reference

7 January 2021

Interleukin-10 determines viral clearance or persistence in vivo

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21627

1 reference

16 August 2017

1 reference